To get started, book a consultation, complete a health questionnaire, and meet with a licensed healthcare provider who will determine whether medical weight loss is appropriate for you and recommend a personalized plan
The pivotal trial, STEP 1, randomized 1,961 adults with a BMI of 30 or higher (or 27 with a weight-related comorbidity) to weekly semaglutide 2.4 mg or placebo, both alongside lifestyle counseling
As a glucagon-like peptide-1 (GLP-1) receptor agonist, Semaglutide mimics the incretin hormones in the body, enhancing insulin secretion in a glucose-dependent manner, suppressing inappropriate glucagon secretion, and slowing gastric emptying to promote satiety and reduce appetite
Efficacy and safety of co-administered once-weekly cagrilintide 24 mg with once-weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial